NRx Pharmaceuticals Expands Mental Health Footprint with Florida Clinic Acquisition
NRx Pharmaceuticals' subsidiary HOPE Therapeutics acquires 49% stake in Cohen and Associates, expanding its mental health services with innovative treatments in Florida.
This acquisition is a pivotal development in the mental health sector, offering hope for patients with severe mood disorders and PTSD through advanced treatments like ketamine and TMS. It also represents a strategic growth opportunity for NRx Pharmaceuticals and HOPE Therapeutics, potentially setting a new standard in psychiatric care delivery and accessibility.